SPNS2 restoration slows leukemia in cell and mouse experiments
A lipid transporter changed how leukemia cells organized the membrane platforms used for growth signals. In a single peer-reviewed study, restoring SPNS2 slowed selected human leukemia cell models and reduced disease burden in mice. The experiments connect membrane chemistry with RAS signaling, while patient-derived analyses link low transporter expression to laboratory drug sensitivity rather than demonstrated clinical benefit.
Science··Midday
A transporter and leukemia growth
Increasing SPNS2, a protein that exports the signaling lipid sphingosine-1-phosphate, reduced the growth of selected acute myeloid leukemia cells. This blood cancer affects immature myeloid cells. The single peer-reviewed experimental study combined human cell lines with mouse models; restoring the transporter also lowered leukemia burden and extended survival in the tested mice. The research began with a functional survey of 426 genes associated with metabolism and cellular stress. Suppressing SPNS2 instead gave leukemia cells a growth advantage.[1]
Membrane lipids reshape signaling
The link involved the cell membrane. Lipid measurements showed less sphingomyelin when the transporter was restored, while imaging revealed changes in the tiny membrane domains where signaling proteins assemble. RAS, a family of proteins involved in growth signaling, showed reduced activity and concentration at these sites. Signals through the associated MEK and ERK proteins also weakened. A transport-impaired SPNS2 variant failed to reproduce the growth suppression, supporting the importance of intact transport activity. The effects were examined in specific leukemia genetic backgrounds, including core-binding-factor leukemia.[1]
Drug sensitivity in experimental systems
Patient-derived resources, including the BEAT AML research dataset, connected lower SPNS2 expression with greater laboratory sensitivity to MEK inhibitors such as trametinib and selumetinib. Separate mouse experiments also supported increased trametinib sensitivity after the gene was suppressed. These observations concern cultured cells, patient-derived measurements and animal experiments, without a human efficacy or safety trial. Some animal comparisons used small groups, and other lipid exporters could still contribute to signaling. The results therefore describe a mechanism and an experimental vulnerability within the leukemia contexts examined.[1]
